Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 13.453
Filtrar
1.
Rev. méd. Urug ; 35(4): 248-257, dic. 2019. tab, fig
Artigo em Espanhol | LILACS | ID: biblio-1026028

RESUMO

El PET (Positron Emission Tomography) con 18-flúor-desoxi-glucosa (18FDG) como radiofármaco es una técnica diagnóstica de medicina nuclear no invasiva cuyas indicaciones fundamentalmente se vinculan con patologías oncológicas. Objetivo: valorar la indicación y el impacto del PET con 18FDG en la atención de mujeres con patología oncológica ginecológica. Estudio: descriptivo retrospectivo mediante la revisión de historias clínicas de las pacientes con cáncer ginecológico asistidas en el Hospital de la Mujer (HM), a las cuales se les realizó un PET con 18FDG en la evaluación diagnóstica o en el seguimiento en el período comprendido entre 1/1/2014 y 31/12/2017. Se analizaron un total de 68 pacientes en las cuales se realizaron 112 PET con 18FDG. En cuanto a la indicación, en los casos de cáncer de cuello (CC), la mayoría (51,5%) de los PET se realizaron ante la sospecha de recidiva; en el cáncer de mama (CM) en el control evolutivo, (44,6%); en los cánceres de endometrio (CE) ante la sospecha de recidiva, (50%); en los cánceres de ovario el 37,5% ante sospecha de recidiva e igual porcentaje en control evolutivo; en los cánceres de vulva (CV) en control postratamiento o sospecha de recidiva, (50% c/u). En cuanto al impacto en la conducta clínica, globalmente, en los casos CC, el 60% de los estudios realizados determinaron modificaciones en la conducta clínica; en los CM, 49%; en los CE, 43%; en los CO, 50%; en los CV, 50%. El PET con 18FDG es una técnica que se ha incorporado a la práctica clínica ginecológica y que requiere aún incorporar las pautas de su utilización.


18 fluoro-2-deoxy-d-glucose (18FDG) PET (Positron Emission Tomography) is a diagnostic non- invasive nuclear medicine imaging technique, and it is usually associated to oncological pathologies. Objective: to assess the indication and impact of 18FDG PET in women with gynecologic cancer. Study: retrospective, descriptive study by reviewing the medical records of patients with gynecologic cancer who were seen at the Women's Hospital. They underwent an 18FDG PET in the diagnostic assessment or follow-up between January 1, 2014 and December 31, 2017. 68 patients were studied, and 112 18FDG PETS were carried out. As to indication, in the case of cervical cancer (CC) most PET studies (51.5%) were used upon suspicion of relapse; in breast cancer to control evolution (44.6%); in endometrial cancer upon suspicion of relapse (50%); in ovarian cancer 37.5% upon suspicion of relapse and same percentage to control evolution; in vulvar cancer in the post-treatment follow-up or upon suspicion of relapse (50% each). As to global impact in the clinical practice, in the case of cervical cancer 60% of the studies resulted in modifications of the clinical behavior; in breast cancer this percentage was 49%; in endometrial cancer it was 43%, in ovarian cancer 50%, and vulvar cancer 50%. 18FDG PET is a technique that has been included in the gynecological clinical practice and guidelines for its use are still required.


O PET (Positron Emission Tomography) com 18-Flúor-Desoxi-Glucosa (18FDG) como radio fármaco, é uma técnica diagnóstica de medicina nuclear não invasiva, cujas indicações fundamentalmente estão vinculadas às patologias oncológicas. Objetivo: avaliar a indicação e o impacto do PET com 18FDG na atenção de mulheres com patologia oncológica ginecológica. Estudo: descritivo retrospectivo feito pela revisão dos prontuários de pacientes com câncer ginecológico atendidas no Hospital de la Mujer (HM), que foram submetidas a PET com 18FDG na avaliação diagnóstica ou no seguimento durante o período compreendido entre 1/1/2014-31/12/2017. Foram analisadas 68 pacientes submetidas a PET com 18FDG. Com relação à indicação, nos casos de câncer de colo de útero (CC) a maioria (51,5%) dos exames PET foi realizada devido à suspeita de recidiva; no câncer de mama (CM) no controle evolutivo (44,6%); nos cânceres de endométrio (CE) devido à suspeita de recidiva (50%); nos cânceres de ovário 37,5% devido a suspeita de recidiva e a mesma proporção no controle evolutivo; nos cânceres de vulva (CV) tanto no controle pós-tratamento com também na suspeita de recidiva (50% c/u). Com relação ao impacto sobre a conduta clínica, de maneira geral nos casos CC, 60% dos estudos realizados determinaram modificações da conduta clínica; nos CM 49%; nos CE 43%; nos CO e nos CV em 50% dos casos. O PET com 18FDG é uma técnica que está sendo incorporar à prática clínica ginecológica sendo necessário incorporar pautas para sua utilização.


Assuntos
Feminino , Tomografia por Emissão de Pósitrons/instrumentação , Neoplasias dos Genitais Femininos/diagnóstico
2.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde, LIS-bvsms | ID: lis-LISBR1.1-46915

RESUMO

Inaugurado em janeiro de 2017, no Instituto Nacional de Câncer (INCA), no Rio de Janeiro, o primeiro ambulatório de sexualidade para pacientes com câncer ginecológico no Brasil está perto de celebrar seu terceiro ano e já se tornou, em 2019, referência nacional para o surgimento de um novo local de atendimento com este enfoque.


Assuntos
Neoplasias dos Genitais Femininos , Instituições de Assistência Ambulatorial
3.
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi ; 37(10): 785-788, 2019 Oct 20.
Artigo em Chinês | MEDLINE | ID: mdl-31726513

RESUMO

Objective: To understand the prevalence of gynecologic diseases among married female workers. Methods: The data of married female workers who underwent occupational health examination in a physical examination center from January to December 2017 were collected. The relationship between the detection of common gynecological diseases, age and occupational types examined by gynecological routine, TCT, breast B-mode ultrasound, uterus and appendix B-mode ultrasound were analyzed. Results: Among the 1142 female workers, the total detection rate of reproductive tract infections was 67.25% (768/1142), the total detection rate of breast-related diseases was 75.22% (859/1142) ; the total detection rate of gynecological tumors and benign lesions was 14.71% (168/1142). The detection rate of breast hyperplasia was the highest 67.08% (766/1142), followed by vaginitis 51.66% (590/1142). Among the abnormalities detected in breast-related diseases, gynecological tumors and benign lesions, the highest detection rate was found in public institutions (85.66% and 27.13%), and the lowest was found in factory workers (70.24% and 7.89%). With the increase of age, the detection rate of breastrelated diseases (breast hyperplasia, breast cyst), gynecological tumors, benign lesions (uterine myoma), and Nessler's cyst abnormalities in married female workers increased (χ(2)(trend)=7.647、21.653、107.411、53.802, P<0.05), while the detection rate of columnar epithelium of cervix decreased (χ(2)(trend)=7.404, P<0.05). There was no significant difference in the total detection rate of reproductive tract infectious diseases (vaginitis, cervical polyps, cervical hypertrophy) among married famale workers of different ages (P<0.05) . Conclusion: The common gynecological diseases of married female workers are affected by many factors such as age and occupation. Health examination and health education should be carried out regularly to reduce the incidence of gynecological diseases among female workers according to different ages and occupations.


Assuntos
Doenças Mamárias/epidemiologia , Doenças dos Genitais Femininos/epidemiologia , Neoplasias dos Genitais Femininos/epidemiologia , Infecções do Sistema Genital/epidemiologia , Feminino , Humanos , Incidência , Ocupações , Prevalência , Ultrassonografia Mamária
4.
Anticancer Res ; 39(10): 5631-5637, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31570460

RESUMO

BACKGROUND/AIM: Pelvic exenteration is a radical procedure for certain advanced or recurrent gynaecological cancers, performed with curative or palliative intent. Its validity has evolved as operative mortality and morbidity have improved. This surgery was evaluated to determine the validity of these claims. PATIENTS AND METHODS: The details of surgery and outcomes of 13 patients who underwent pelvic exenteration (6 curative intent, 7 palliative intent) for advanced or recurrent gynaecological cancers in our Department were retrospectively evaluated. RESULTS: There were no significant differences in blood loss, surgical time, hospital stay, and complications between curative pelvic exenteration and palliative pelvic exenteration. The curative intent group had a good prognosis; the palliative-intent group showed a trend to a worse prognosis. All patients' symptoms were relieved, but in patients with short survival, symptom relief lasted for up to 3 months. CONCLUSION: Pelvic exenteration is an acceptable and valuable procedure for gynaecological cancers.


Assuntos
Neoplasias dos Genitais Femininos/cirurgia , Recidiva Local de Neoplasia/cirurgia , Adulto , Idoso , Feminino , Neoplasias dos Genitais Femininos/mortalidade , Ginecologia/métodos , Humanos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/mortalidade , Duração da Cirurgia , Exenteração Pélvica/métodos , Complicações Pós-Operatórias/cirurgia , Estudos Retrospectivos , Adulto Jovem
5.
Gynecol Oncol ; 155(2): 301-304, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31575390

RESUMO

OBJECTIVE: Pegylated liposomal doxorubicin (PLD) has similar reported clinical efficacy compared with conventional doxorubicin with less cardiotoxicity. The manufacturer of PLD advises that cardiac function should be evaluated with endomyocardial biopsy, echocardiography or multigated radionucleotide scan (MUGA) pre-treatment and during therapy. This study was designed to assess the necessity of pre-treatment cardiac evaluation in patients receiving PLD. METHODS: After IRB approval, a retrospective study of all women with gynecologic cancer who received PLD from 2006 to 2018 was performed. Demographic information, treatment records, cardiac risk factors, and cardiac surveillance testing were examined. Wilcoxon signed rank sum test and logistic regression were used to evaluate the association of cumulative PLD exposure with cardiotoxicity. RESULTS: A total of 235 patients received PLD for gynecologic cancer. Patients received a median of 3 cycles of PLD with a cumulative dosage of 237 mg over a median follow-up time of 24 months. Sixteen patients in the cohort (7%) had no cardiac surveillance at all. Of the remaining patients who underwent cardiac testing, 183 (84%) received MUGA scans and 36 (16%) had echocardiography. Of the 56 patients who had both pre- and post-treatment cardiac testing, there was no significant difference in median ejection fraction (p = 0.17). Three patients developed PLD-associated cardiac toxicity but only one patient had severe manifestations requiring discontinuation of PLD therapy. CONCLUSIONS: Routine cardiac testing before, during or after treatment with PLD may be unnecessary. Cardiac testing may be more appropriate for individual patients for whom the clinical suspicion of PLD-related cardiac toxicity is high.


Assuntos
Antibióticos Antineoplásicos/administração & dosagem , Doxorrubicina/análogos & derivados , Neoplasias dos Genitais Femininos/tratamento farmacológico , Cardiopatias/induzido quimicamente , Doxorrubicina/efeitos adversos , Substituição de Medicamentos , Ecocardiografia/métodos , Feminino , Cardiopatias/fisiopatologia , Cardiopatias/prevenção & controle , Humanos , Pessoa de Meia-Idade , Imagem Multimodal/métodos , Polietilenoglicóis/efeitos adversos , Angiografia Cintilográfica/métodos , Estudos Retrospectivos , Volume Sistólico/efeitos dos fármacos
6.
Pan Afr Med J ; 33: 130, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31558929

RESUMO

Introduction: Cancer is a public health problem that affect women more than men. The aim of the study was to describe the epidemiological and histopathological features of gynecological malignancies in the city of Yaoundé, Cameroon. Methods: This was a descriptive cross-sectional study of histologically proven gynecological cancers over a 10-year period (2008-2017) in the Gynecology and Pathological Anatomy Departments of the University Teaching Hospital of Yaoundé. Results: A total of 682 cancers were identified among which, 342 gynecological cancers, for an overall frequency of 50.1% and an annual frequency of 34.2 cases on average. There was a trend suggesting an increase annual frequency over time. The cervix was the most frequent location with 182 cases (53.2%); followed by breast with 96 cases (28.1%); endometrium with 33 cases (9.7%) and ovaries 15 cases (4.4%). These patients were on average 51.9±13.7 years old, mostly housewives (56.8%), married (60.4%), multiparous (61.3%) and referred (62.6%). Histopathologically, cervical cancer was predominantly squamous cell carcinoma (86.8%), invasive (80.9%) and well differentiated (45.5%). For breast cancers, the majority were ductal carcinomas (78.1%), invasive (92%), and histological grade SBR II (50.6%). The most common histopathological types of endometrial and ovarian cancer were adenocarcinoma (72.2%) and serous cystadenocarcinoma (46.7%), respectively. Conclusion: Gynecological cancers are common. Screening is expected to increase at 30 years for cervical cancer and start at age 40 with mammography for breast cancer.


Assuntos
Neoplasias da Mama/epidemiologia , Neoplasias dos Genitais Femininos/epidemiologia , Programas de Rastreamento/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias da Mama/patologia , Camarões/epidemiologia , Carcinoma Ductal de Mama/epidemiologia , Carcinoma Ductal de Mama/patologia , Estudos Transversais , Neoplasias do Endométrio/epidemiologia , Neoplasias do Endométrio/patologia , Feminino , Neoplasias dos Genitais Femininos/patologia , Hospitais Universitários , Humanos , Pessoa de Meia-Idade , Neoplasias Ovarianas/epidemiologia , Neoplasias Ovarianas/patologia , Neoplasias do Colo do Útero/epidemiologia , Neoplasias do Colo do Útero/patologia , Adulto Jovem
7.
Gynecol Oncol ; 155(1): 93-97, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31492539

RESUMO

OBJECTIVE: To compare postoperative outcomes by primary payer status for patients with gynecologic malignancies. METHODS: We retrospectively reviewed patients who underwent elective surgery for gynecologic malignancies between 2015 and 2019. Patient outcomes were compared by payer status using logistic regression. Sociodemographic and clinical covariates were selected a priori and included age, American Society of Anesthesiologists physical status classification, body mass index, smoking status, malignancy site, surgery type, race, estimated income, marital status, and medical interpreter requirement. RESULTS: A total of 1894 patients comprised the study sample. In the multivariate model, compared to patients with private insurance, Medicaid and Medicare patients were more likely to mobilize >24 h after surgery (OR 1.9, p < 0.05 and OR 3.2, p < 0.001, respectively), to require ICU admission (OR 4.0, p < 0.05 and OR 5.0, p < 0.05, respectively), and to have longer lengths of stay (OR 1.8, p < 0.05 and OR 2.2, p < 0.001, respectively). Medicaid patients were also more likely to have higher total hospital costs (OR 1.7, p < 0.05). Payer status was not associated with postoperative pain, postoperative opiate use, or 30-day readmission rates. CONCLUSIONS: Medicaid and Medicare payer status are associated with worse postoperative outcomes in patients with gynecologic malignancies. The poor outcomes of Medicaid patients - a cohort defined by limited income - are noteworthy. The etiology is likely multifactorial, arising from a complex interplay of factors ranging from system issues such as access to care to the unique health status of a population bearing a high burden of disease and socioeconomic adversity.


Assuntos
Neoplasias dos Genitais Femininos/economia , Neoplasias dos Genitais Femininos/cirurgia , Disparidades em Assistência à Saúde/estatística & dados numéricos , Medicaid/estatística & dados numéricos , Medicare/estatística & dados numéricos , Feminino , Procedimentos Cirúrgicos em Ginecologia/economia , Procedimentos Cirúrgicos em Ginecologia/estatística & dados numéricos , Custos Hospitalares , Humanos , Tempo de Internação , Pessoa de Meia-Idade , Dor Pós-Operatória/tratamento farmacológico , Dor Pós-Operatória/economia , Dor Pós-Operatória/etiologia , Readmissão do Paciente/estatística & dados numéricos , Estudos Retrospectivos , São Francisco , Resultado do Tratamento , Estados Unidos
8.
Gynecol Oncol ; 155(2): 283-286, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31519318

RESUMO

PURPOSE: The aim of our review was to ascertain factors associated with the successful completion of a randomized controlled trial in gynecological oncology. MATERIALS AND METHODS: This retrospective cohort study utilized data collected from the National Institutes of Health's US National Library of Medicine database on ClinicalTrials.gov. Data was collected over a five year period (2009-2013). Utilizing the search terms under the National Institutes of Health recommended "Studies by Topics" gynecological oncology studies were identified. Randomized controlled trials were selected for based on intervention and randomization criteria. Elements were then compared with statistical analysis performed using SASS. RESULTS: As of September 1st 2018, 149 of the 318 identified randomized controlled trials were successfully completed over a median length of 44 months (IQR 30.0-55.0). Completed randomized controlled trials were more likely to be performed at single centers (p < 0.005). Interventional, drug and device trials were not significantly more likely to be completed. There was no difference in funding sources for completed or not completed randomized controlled trials. CONCLUSIONS: Prospective randomized trials are essential for establishing the standard of care in clinical medicine. They are, however, time and resource intensive. Herein we have attempted to identify factors associated with successful and timely completion of gynecologic oncology randomized controlled trials including site of origin, number of participating sites, funding source, intervention type, enrollment size, and study length; however, none of these factors were observed to have an association with increased rates of trial publication.


Assuntos
Neoplasias dos Genitais Femininos/terapia , Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos , Feminino , Neoplasias dos Genitais Femininos/economia , Humanos , Estudos Multicêntricos como Assunto/economia , Estudos Multicêntricos como Assunto/estatística & dados numéricos , Estudos Prospectivos , Editoração/estatística & dados numéricos , Ensaios Clínicos Controlados Aleatórios como Assunto/economia , Apoio à Pesquisa como Assunto , Estudos Retrospectivos
9.
Complement Ther Clin Pract ; 36: 88-93, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31383451

RESUMO

BACKGROUND: Indigenous Australian women experience worse gynaecological cancer outcomes than non-Indigenous women. While traditional and complementary medicine (T&CM) is increasingly used by cancer patients alongside conventional treatments, little is known about T&CM use by Indigenous women. This study aimed to explore the beliefs, attitudes and experiences related to T&CM use and disclosure among Indigenous women undergoing gynaecological cancer investigations. METHODS: A mixed-methods design explored T&CM use among Indigenous women who presented for gynaecological cancer investigation at an urban Queensland hospital (September 2016 and January 2018). RESULTS: Fourteen women participated. The reported use (86%) and perceived value of T&CM was high among the participants, however, women reported major challenges in communicating with healthcare providers about T&CM, commonly associated with trust and rapport. CONCLUSIONS: These findings highlight the need for strategies to facilitate culturally-appropriate doctor-patient communication around T&CM to foster trust and transparency in gynaecological cancer care for Indigenous women.


Assuntos
Terapias Complementares , Neoplasias dos Genitais Femininos , Conhecimentos, Atitudes e Prática em Saúde/etnologia , Medicina Tradicional , Grupo com Ancestrais Oceânicos/etnologia , Austrália , Feminino , Neoplasias dos Genitais Femininos/etnologia , Neoplasias dos Genitais Femininos/terapia , Humanos
10.
Gynecol Oncol ; 155(1): 119-125, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31405609

RESUMO

OBJECTIVES: To quantify, and identify predictors of, post-discharge opioid use in gynecologic oncology patients undergoing minimally invasive hysterectomy (MIH). METHODS: For this prospective cohort study, gynecologic oncology patients planning to undergo MIH were recruited at a single institution. Post-operative opioid usage was evaluated via chart review and surveys at 1-2-week and 4-6-week post-operative visits. Opioids are converted to oral morphine milligram equivalents (MME) for standardization. Descriptive statistics and modified Poisson regression were used to quantify opioid requirements and evaluate predictors of post-discharge opioid use respectively. RESULTS: One hundred eighteen eligible women underwent MIH. Of these, 108 had complete data at both follow-up timepoints. Malignancy was present in 79% of cases, 71% of which were endometrial cancer. Most surgeries were laparoscopic (73%). Median hospital stay was 1 night (IQR 1-1). Inpatients received a median of 30.75 MME (IQR 7.5-52.5 MME). Twenty-three women (21.3%) used no opioids while inpatient. At the 1-2-week follow-up median usage was 6 pills of 5 mg oxycodone, or 45 MME (IQR 0-15.5 pills). After complete follow-up, median post-discharge usage was 10 pills, or 75 MME (IQR 0-22.5 pills) and 36 participants (33.33%) used no opioids after hospital discharge. The median prescription was for 30 pills (range 10-60). Above median inpatient opioid use was associated with an increased risk of above median opioid usage after hospital discharge (RR 2.31, 95% CI 1.38-3.87) on multivariable analysis. CONCLUSIONS: In this cohort, opioids were overprescribed relative to use. Inpatient use was the strongest predictor of post-discharge opioid use. More restrictive, and personalized, opioid prescribing practices may be a pathway to reduce opioid misuse and diversion. PRéCIS: Opioids were overprescribed by a factor of three to gynecologic oncology patients, whose inpatient opioid requirement predicted post-discharge opioid needs after minimally invasive hysterectomy.


Assuntos
Analgésicos Opioides/administração & dosagem , Neoplasias dos Genitais Femininos/cirurgia , Prescrição Inadequada , Dor Pós-Operatória/tratamento farmacológico , Estudos de Coortes , Feminino , Procedimentos Cirúrgicos em Ginecologia/efeitos adversos , Humanos , Histerectomia/efeitos adversos , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos/efeitos adversos , Dor Pós-Operatória/etiologia , Estudos Prospectivos
11.
Health Psychol ; 38(10): 866-877, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31368718

RESUMO

OBJECTIVE: Elevated body mass index (BMI), tobacco use, and sleep disturbance are common health concerns among women with gynecologic cancers. The extent to which these factors are associated with systemic inflammation in gynecologic cancers is unknown. This is a significant literature gap given that (a) chronic, systemic inflammation may mediate relationships between behavioral health factors and cancer outcomes; and (b) elevated BMI, tobacco use, and sleep disturbances can be modified via behavioral interventions. This study examined Interleukin-6 (IL-6) relations with BMI, tobacco use history, and sleep disturbances in patients undergoing surgery for suspected gynecologic cancer. METHOD: Participants were 100 women (M age = 58.42 years, SD = 10.62 years) undergoing surgery for suspected gynecologic cancer. Smoking history was determined by participant self-report. Sleep quality/disturbance was assessed via the Pittsburgh Sleep Quality Index. BMI was abstracted from electronic health records. Presurgical serum IL-6 concentrations were determined using Enzyme-Linked Immunosorbent Assay. RESULTS: Controlling for the cancer type and stage, regression analyses revealed higher BMI, ß = 0.258, p = .007, and former/current smoking status, ß = 0.181, p = .046, were associated with higher IL-6. IL-6 did not differ between former and current smokers, ß = 0.008, p = .927. Global sleep quality, sleep latency, and sleep efficiency were not associated with IL-6. CONCLUSIONS: Higher BMI and any history of tobacco use predicted higher IL-6 among women undergoing surgery for suspected gynecologic cancers. Cognitive-behavioral interventions targeting primary and secondary obesity and tobacco use prevention may reduce systemic inflammation and optimize cancer outcomes in this population. (PsycINFO Database Record (c) 2019 APA, all rights reserved).


Assuntos
Índice de Massa Corporal , Neoplasias dos Genitais Femininos/sangue , Interleucina-6/sangue , Obesidade/sangue , Transtornos do Sono-Vigília/sangue , Uso de Tabaco/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco
12.
Gynecol Oncol ; 155(1): 98-104, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31378375

RESUMO

OBJECTIVE: To evaluate associations between US region of residence and urbanization and the place of death among women with gynecologic malignancies in the United States. METHODS: A retrospective cross-sectional study was performed using publicly available death certificate data from the National Center for Health Statistics. All gynecologic cancer deaths were included from 2006 to 2016. Comparisons among categories were performed with a two-tailed chi-square test, with p-values <0.05 considered significant. RESULTS: From 2006 to 2016, 328,026 women died from gynecologic malignancies in the US. Of these deaths, 40.1% (n = 134,333) occurred in the patient's home, 24.9%(n = 81,823) in the hospital, and 11.3% (37,188) in an inpatient hospice facility. Place of death varied by geographic region. The Northeast had the largest percentage of gynecologic cancer patients (31.3%) die as a hospital inpatient. The West had the highest percentage of deaths (49.3%) at home. Deaths in a hospice facility were the highest (14.1%) in the South. Place of death varied by urbanization; patients residing in large central metro or rural counties were the most likely to die during hospital admission (28.7% and 27.1%, respectively). Patients living in medium-sized metro areas were the least likely to die in hospitals (21.8%) and most likely to die in a hospice facility (14.3%). All comparisons were significant by study definition. CONCLUSION: The place of death for patients with gynecologic malignancies varies by US region and urbanization. These disparities are multifactorial in nature, likely influenced by both sociodemographic factors and regional resource availability. In this study, however, rural and central metro areas are identified as regions that may benefit from further hospice development and advocacy.


Assuntos
Neoplasias dos Genitais Femininos/mortalidade , Adolescente , Adulto , Grupo com Ancestrais do Continente Africano/estatística & dados numéricos , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Estudos Transversais , Grupo com Ancestrais do Continente Europeu/estatística & dados numéricos , Feminino , Neoplasias dos Genitais Femininos/etnologia , Humanos , Lactente , Recém-Nascido , Pessoa de Meia-Idade , Estudos Retrospectivos , População Rural/estatística & dados numéricos , Estados Unidos/epidemiologia , População Urbana/estatística & dados numéricos , Adulto Jovem
13.
J Comput Assist Tomogr ; 43(6): 825-834, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31453978

RESUMO

Accurate oncological staging for early detection is of utmost importance in patient care and increasing the overall patient survival outcome. Hybrid imaging in the form of positron emission tomography (PET)/computed tomography has been successfully implemented in oncological imaging and, where available, has been used consistently in patients with gynecologic malignancies. The implementation of PET/magnetic resonance imaging (MRI) enables high-quality assessment of gynecological malignancies by combining the diagnostic advantages of metabolic information of PET along with the high-resolution anatomical and functional information from the MRI to provide precise information about staging, recurrence, and metastases. This article will review the various applications of PET/MRI in gynecological cancer.


Assuntos
Neoplasias dos Genitais Femininos/diagnóstico por imagem , Recidiva Local de Neoplasia/diagnóstico por imagem , Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos , Feminino , Humanos , Metástase Neoplásica , Estadiamento de Neoplasias
14.
Int J Gynaecol Obstet ; 147(2): 252-257, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31420876

RESUMO

OBJECTIVE: To retrospectively review the efficacy and safety of novel direct oral anticoagulants (DOACs) and compare the results with those of vitamin K antagonists (VKA) when used in clinical practice to treat venous thromboembolism (VTE) because there is insufficient evidence regarding its use in patients with gynecological cancers. METHODS: A study was conducted of patients diagnosed with gynecological cancers at Osaka University Hospital between January 2010 and December 2017. The medical records of those who suffered from deep venous thrombosis (DVT) and/or pulmonary embolism (PE) were retrospectively reviewed. RESULTS: Among the 1698 cases of gynecological cancers, 107 (6.3%) cases were diagnosed as having VTE. A total of 34 (31.8%) patients presented DVT plus PE and 73 (68.2%) patients had DVT alone. Fifty-four cases were treated with DOACs and 53 with VKA. Although 3 of the 53 patients (5.7%) in the VKA group developed recurrent VTE, only 1 (1.9%) patient in the DOAC group showed clinically relevant bleeding from a tumor penetrating the rectum. DOACs were non-inferior to VKA with respect to the composite outcome, including recurrent venous thrombosis and relevant bleeding (hazard ratio 0.31, 95% confidence interval 0.03-3.12, P=0.363). CONCLUSION: DOACs can be effectively and safely used in VTE patients with gynecological cancers.


Assuntos
Anticoagulantes/administração & dosagem , Heparina/administração & dosagem , Tromboembolia Venosa/tratamento farmacológico , Vitamina K/antagonistas & inibidores , Administração Oral , Idoso , Feminino , Neoplasias dos Genitais Femininos/epidemiologia , Humanos , Pessoa de Meia-Idade , Estudos Retrospectivos , Tromboembolia Venosa/epidemiologia
15.
Gynecol Oncol ; 155(1): 161-169, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31422857

RESUMO

Effective communication between gynecologic oncology providers and patients is vital to patient-centered care. Skilled communication improves the patient's knowledge retention, builds trust in providers, enhances shared decision-making, and alleviates anxiety of both patients and caregivers. Effective communication is also associated with reduced provider burnout due to improved comfort from possessing the skills to handle emotionally charged situations. Therefore, training in serious illness communication skills is critically important to gynecologic oncology practice and benefits patients, providers, and the healthcare system. Like surgical skills, communication skills can be learned and improved upon, particularly by making use of communication skills courses and other resources. While the purpose of each conversation will vary based on the medical setting, most communication roadmaps incorporate four basic components: 1) Assess patient knowledge and understanding, 2) inform patient in accordance with her communication preferences, 3) recognize and respond to emotion 4) elicit patient values, and create a plan that aligns with those values. Improved patient outcomes associated with addressing patient emotions underscore a critical need to recognize and address emotional cues during difficult conversations. We present strategies for delivering serious news, and for discussing prognosis and goals of care. In each strategy, we highlight skills for recognizing and responding to patient and family emotional cues.


Assuntos
Neoplasias dos Genitais Femininos/psicologia , Relações Médico-Paciente , Comunicação , Barreiras de Comunicação , Tomada de Decisões , Feminino , Humanos , Oncologistas/psicologia
16.
Anticancer Res ; 39(8): 4555-4560, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31366559

RESUMO

BACKGROUND/AIM: Treatments for controlling delayed nausea after chemotherapy are inadequate, potentially inciting malnutrition. We sought to determine the incidence of nausea, anorexia, and food intake after chemotherapy. PATIENTS AND METHODS: Subjects were females with gynecological cancers who underwent chemotherapy between 2008 and 2013. Nausea, anorexia, and food intake in the acute (day 1) and delayed phases (days 2 and 3) were retrospectively evaluated. RESULTS: Subjects included 156 females. Chemotherapies were highly (HEC; n=24) and moderately emetogenic (MEC; n=132). There were no significant between-group differences for anorexia control during either the acute or the delayed phase and both groups demonstrated significantly worse control of nausea during the delayed phase. In the HEC group, food intake was significantly reduced on days 2 and 3 compared with day 1. CONCLUSION: Rates of nausea, anorexia, and food intake significantly worsened over time, particularly in the MEC group. Current supportive therapies appear inadequate and should be improved.


Assuntos
Anorexia/epidemiologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Ingestão de Alimentos , Neoplasias dos Genitais Femininos/tratamento farmacológico , Adulto , Idoso , Anorexia/patologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Feminino , Neoplasias dos Genitais Femininos/complicações , Neoplasias dos Genitais Femininos/epidemiologia , Neoplasias dos Genitais Femininos/patologia , Humanos , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Náusea/epidemiologia , Náusea/patologia , Vômito/induzido quimicamente , Vômito/epidemiologia , Vômito/patologia
17.
Stud Health Technol Inform ; 264: 704-708, 2019 Aug 21.
Artigo em Inglês | MEDLINE | ID: mdl-31438015

RESUMO

Clinical Decision Support System (CDSS) has been implemented to support physicians about the medical prescription of genetic testing. CDSS is based on open source software. A CDSS for prescribing these genetic tests in BRCA1 and BRCA2 and preventing gynecological cancer risks has been designed and performed in the 'Virgen del Rocío' University Hospital. Clinical evidence demonstrates that BRCA1 and BRCA2 mutations can develop gynecological cancer, but genetic testing has a high cost to the healthcare system. The developed technological architecture integrates open source tools like Mirth Connect and OpenClinica. The system allows general practitioners and gynecologists to classify patients as low risk (they do not require a specific treatment) or high risk (they should be attended by the Genetic Council), According to their genetic risk, recommending the prescription of genetic tests. The aim main of this paper is the evaluation of the developed CDSS, getting positive outcomes.


Assuntos
Neoplasias da Mama , Sistemas de Apoio a Decisões Clínicas , Neoplasias dos Genitais Femininos , Feminino , Testes Genéticos , Humanos , Prescrições , Fatores de Risco , Software
18.
Medicine (Baltimore) ; 98(30): e16366, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-31348237

RESUMO

RATIONALE: Primary melanomas of the female genital tract are rare and usually occur in the vulva and vagina. Involvement of the cervix, uterus, and ovary are extremely rare. Surgery and adjuvant therapy remain the mainstay of treatment. The majority of patients experience poor long-term survival. This report aimed at highlighting an extremely rare case of primary melanoma of the female genitalia, synchronously involving the vulva and uterine cervix. PATIENT CONCERNS: A 58-year-old multiparous female presented with postmenopausal bleeding for 10 days. DIAGNOSES: Speculum examination and histologic analysis of the surgical specimens revealed synchronous involvement of the vulva and uterine cervix by malignant melanoma. According to the American Joint Committee on Cancer stage grouping for melanoma, this tumor was at stage V. INTERVENTIONS: The patient subsequently underwent radical surgery and postoperative chemotherapy. OUTCOMES: She has been on regular follow-up, and is now free of disease for 50 months after the operation. LESSONS: Primary melanomas of the female genital tract have biologically aggressive characteristics. Optimal management consists of individualized surgery and adjuvant therapy. However, early recognition and prompt intervention offer maximal benefit from treatment.


Assuntos
Neoplasias dos Genitais Femininos/patologia , Melanoma/patologia , Colo do Útero/patologia , Feminino , Neoplasias dos Genitais Femininos/terapia , Humanos , Melanoma/terapia , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Vulva/patologia
19.
Gynecol Oncol ; 154(3): 616-621, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31324452

RESUMO

OBJECTIVE: Patients are increasingly using online materials to learn about gynecologic cancer. Providers can refer patients to online educational materials produced by a number of different major medical organizations and pharmacology companies. The National Institutes of Health (NIH) and the American Medical Association (AMA) recommend that patient educational materials (PEMs) are written between a sixth and eighth grade reading level. In this study, we assess the readability of online PEMs published by major medical organizations and industry partners. METHODS: Websites from twelve websites providing educational materials for gynecologic oncology patients were surveyed. Online PEMs were identified and analyzed using seven validated readability indices. One-way ANOVA and Tukey's Honestly Significant Difference (HSD) post-hoc analysis were performed to detect differences in readability between publishers. RESULTS: Two-hundred and sixty PEMs were included in this analysis. Overall, PEMs were written at a mean 11th±0.6 grade reading level. Only 6.5% of articles were written at the AMA/NIH recommended reading grade level of 6th to 8th grade or below. ANOVA demonstrated a significant difference in readability between publishing associations (p<0.01). PEMs from the Centers for Disease Control had a mean 9th±1.2 grade reading level and were significantly lower than all other organizations. PEMs from The Foundation for Women's Cancer had a mean 13th±1.8 grade reading level and were significantly higher than most other organizations. PEMs from pharmaceutical companies (mean readability=10.1±1.1, N=30) required the lowest reading grade level and were significantly more readable than those from governmental organizations (11.1±1.7, p<0.05) and nonprofit medical associations (12.4±1.7, p<0.01) in ANOVA and Tukey-Kramer post hoc analysis. CONCLUSIONS: Gynecologic oncology PEMs available from twelve major organization websites are written well above the recommended sixth to eighth grade reading difficulty level.


Assuntos
Neoplasias dos Genitais Femininos , Internet/normas , Educação de Pacientes como Assunto/normas , Leitura , Compreensão , Indústria Farmacêutica , Feminino , Órgãos Governamentais , Alfabetização em Saúde , Humanos , Organizações sem Fins Lucrativos , Educação de Pacientes como Assunto/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA